GB2454615A - Antidiabetic azabicyclo (3.1.0) hexan compounds - Google Patents

Antidiabetic azabicyclo (3.1.0) hexan compounds Download PDF

Info

Publication number
GB2454615A
GB2454615A GB0902845A GB0902845A GB2454615A GB 2454615 A GB2454615 A GB 2454615A GB 0902845 A GB0902845 A GB 0902845A GB 0902845 A GB0902845 A GB 0902845A GB 2454615 A GB2454615 A GB 2454615A
Authority
GB
United Kingdom
Prior art keywords
compounds
hexan
antidiabetic
azabicyclo
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0902845A
Other versions
GB0902845D0 (en
Inventor
Sudershan Kumar Arora
Neelima Sinha
Prathap Nair
Ajay Tilekar
Nabendu Saha
Talha Khan
Reeba Vikramadithyan
Rajesh Gupta
Sai Kumar Chakka
Navnath Popat Karche
Prasad Purushottam Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of GB0902845D0 publication Critical patent/GB0902845D0/en
Publication of GB2454615A publication Critical patent/GB2454615A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, their tautomeric forms, their stereoisomers, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of diabetes and related diseases.
GB0902845A 2006-07-21 2007-07-20 Antidiabetic azabicyclo (3.1.0) hexan compounds Withdrawn GB2454615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN730KO2006 2006-07-21
PCT/IN2007/000298 WO2008010238A2 (en) 2006-07-21 2007-07-20 Antidiabetic azabicyclo [3. 1. 0] hexan compounds

Publications (2)

Publication Number Publication Date
GB0902845D0 GB0902845D0 (en) 2009-04-08
GB2454615A true GB2454615A (en) 2009-05-13

Family

ID=38812084

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0902845A Withdrawn GB2454615A (en) 2006-07-21 2007-07-20 Antidiabetic azabicyclo (3.1.0) hexan compounds

Country Status (3)

Country Link
AU (1) AU2007274598A1 (en)
GB (1) GB2454615A (en)
WO (1) WO2008010238A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
FR2932479A1 (en) * 2008-06-13 2009-12-18 Servier Lab NOVEL AZABICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2758041B1 (en) 2011-09-20 2021-01-13 Basf Se Low-molecular modulators of the cold-menthol receptor trpm8 and use of same
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
TW202108559A (en) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead inhibitors and uses thereof
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN110237045A (en) * 2019-07-11 2019-09-17 广西大学 A kind of capsule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062872A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl-2-hydroxypropionic acid derivative (i)
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062872A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl-2-hydroxypropionic acid derivative (i)
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol. 16, No. 15, 2006, (Kuhn; Hilpert B et al), pages 4016 - 4020, ISSN 0960-894X *
JOURNAL OF MEDICINAL CHEMISTRY, Vol. 45, No. 4, 2002, (SAUERBERG PER; ET AL), pages 789 - 804, ISSN 0022-2623 *

Also Published As

Publication number Publication date
AU2007274598A1 (en) 2008-01-24
WO2008010238A3 (en) 2008-04-17
GB0902845D0 (en) 2009-04-08
WO2008010238A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
EA201270492A1 (en) COMPOUNDS FOR THE TREATMENT OF DISLIPIDEMIC AND RELATED DISEASES
MX2011012337A (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases.
UA98961C2 (en) Pyrazinone derivatives and their use in the treatment of lung diseases
MX2010009922A (en) Pyridazinone glucokinase activators.
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
MX2009010059A (en) Quinoline derivatives for the treatment of inflammatory diseases.
MX2012001985A (en) 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazine derivatives.
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
EA201001585A1 (en) DERIVATIVES OF THYENOPYRIDONE AS AMP-ACTIVATED PROTEINKINASE (AMRC) ACTIVATORS
MX2009006742A (en) Novel compounds.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
TW200833663A (en) Therapeutic agents
UA93393C2 (en) 1,3-dioxane carboxylic acids
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
DE602008001725D1 (en) 1- (1-BENZYLPIPERIDIN-4-YL) BENZIMIDAZOLE-5-CARBOXYLENE DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2009006010A (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases.
TW200716547A (en) Piperidin-4-yl-amide derivatives
MY146802A (en) Novel drugs for treating respiratory diseases
MX2009005544A (en) Indoles.

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)